Biogen Idec Names Chief Strategy OfficerBy
Biogen Idec has appointed Adam M. Koppel, M.D., Ph.D., as senior vice president and chief strategy officer, effective May 15, 2014.
Dr. Koppel will be responsible for leading corporate strategy and portfolio management, as well as ensuring that disease strategies clearly align with the corporate strategy. He will report to George Scangos, Ph.D., chief executive officer, and will be a member of the Biogen Idec management team.
Dr. Koppel will join Biogen Idec from Brookside Capital, the public equity affiliate of Bain Capital, where he joined in 2003, serving as a managing director since 2009. Prior to Brookside Capital, he was an associate principal of the McKinsey Healthcare Practice. He holds bachelor and master of Arts degrees in history and science from Harvard College and earned an MD and PhD. in molecular neurobiology from the University of Pennsylvania. He also received an MBA from the University of Pennsylvania's Wharton School.
Source: Biogen Idec